|
|
IVAC Commends India on Major Polio Milestone - 1 Year With No New Cases January 13, 2012 IVAC commends India, partners such as Rotary International, WHO, UNICEF, CDC, the millions of community leaders, health workers, volunteers and the global health community on this important milestone: reaching 1 year without a new case of wild poliovirus. This could never have been accomplished without the commitment and leadership of all. This is an important step forward for both India and the world in the fight to stop this debilitating disease. IVAC supports continuing efforts to immunize against polio and other deadly diseases to help ensure a healthy future for all children. Read more about this milestone and what it means for India and other polio-endemic countries. Learn about Pneumonia Etiology Research for Child Health (PERCH)! January 11, 2012 Click here to find out more about IVAC’s PERCH study, recently mentioned by Melinda Gates in her interview with Nick Kristof in The New York Times. Hib in India: Progress and Hope December 14, 2011 IVAC's Dr. Mathu Santosham reflects on today's introduction of the Hib vaccine in the Indian state of Kerala, and his hope for the children of India. Read more about this historic event on the IVAC Blog. GAVI takes first steps to introduce vaccines against cervical cancer and rubella November 18, 2011 Responding to demand from developing countries, the GAVI Alliance will take the first steps towards the introduction of Human papillomavirus (HPV) and rubella vaccines in developing countries, the GAVI Board announced on Thursday, November 17. If negotiations to secure a sustainable price from manufacturers are successful and countries can demonstrate their ability to deliver the vaccines, up to two million women and girls in nine countries could be protected from cervical cancer by 2015. Responding to projected demand from 30 countries and World Health Organization (WHO) recommendations, the Board also agreed to open a funding window for vaccines against the rubella virus, which threatens pregnancies and child health. The plan is to reach 588 million children by 2015. “These two initiatives have huge potential impact for women and families in the developing world,” said Seth Berkley MD, CEO of GAVI, which supports seven other vaccines. Read more about this important news from GAVI IVAC's Work Featured in PBS NewsHour Report about PCV in Nicaragua November 12, 2011 PBS Correspondent Ray Suarez speaks with IVAC's Dr. Orin Levine and GAVI's Dr. Seth Berkley about Nicaragua's fight against pneumonia using the Pneumococcal Conjugate Vaccine, and the price mechanisms used to implement the vaccine's introduction in the country. Watch the report. New research examines cost-effectiveness of PCV in low- and middle-income countries November 11, 2011 In a paper published November 9, 2011 in the journal International Health, research led by Dr. Anushua Sinha estimates that two pneumococcal vaccines being introduced in the world’s poorest countries with support from the GAVI Alliance could save the lives of 3 to 4 million children over the next 10 years, and indicate that the vaccines are a highly cost-effective investment for developing countries. With GAVI’s support, 15 of the world’s poorest countries have introduced the newest-generation vaccines that protect against pneumococcal disease. Nearly 60 countries are expected to introduce this vaccine by 2015. "Policy-makers increasingly rely on cost-effectiveness analysis, in addition to clinical effectiveness, when considering the introduction of new childhood vaccines. A previous analysis determined vaccination of infants with 7-valent pneumococcal conjugate vaccine (PCV) to be highly cost effective in preventing child mortality in countries eligible for financial support from the Global Alliance for Vaccines and Immunization (GAVI). We aimed to update this analysis by incorporating recent data on global disease burden, indirect effects and higher valency vaccines." In a separate paper, published in the same issue of the journal, the researchers also examined the economic impact of PCV in middle-income countries. Their findings indicate that "Vaccination would be cost effective for 72 countries with the 7-valent vaccine and for all countries with the 10- or 13-valent vaccines. The economic case for vaccination is compelling for middle-income countries." 2011 Pneumonia Progress Report is Released November 8, 2011 An annual production by the International Vaccine Access Center (IVAC) at Johns Hopkins Bloomberg School of Public Health, the 2011 Pneumonia Progress Report examines data on several key pneumonia interventions – including exclusive breastfeeding, access to a health care facility, antibiotic treatment and vaccination against pneumonia’s four leading causes – in the 15 countries with the most child pneumonia deaths. Read more about this year's Progress Report here. New Research: Worldwide Child Mortality from Rotavirus Remains High October 25, 2011 Findings from a study published today in the Lancet show that child mortality from rotavirus remains high. 95% of these deaths occurred in countries that are eligible for vaccine subsidies through GAVI, representing a tremendous opportunity to save lives with rotavirus vaccines. Learn more about this new research. IVAC's Deputy Director Honored by President Obama October 17, 2011 Dr. Katherine O'Brien MD, IVAC's Deputy Director, was among the scientists honored by President Obama, as they received the Presidential Early Career Awards for Scientists and Engineers, the highest honor bestowed by the United States government on science and engineering professionals in the early stages of their independent research careers. For more, see the White House's announcement and a photo from the East Room. From the Field: Pneumococcal Vaccine Research in The Gambia September 22, 2011 Dustin Gibson, a PhD Student in International Health at Johns Hopkins Bloomberg School of Public Health talks about his research on vaccine delivery and pneumonia case detection in The Gambia. Read his story here. A vaccine's whisper of hope: Perspectives from Kenya September 9, 2011 IVAC's Director of Epidiemiology, Dr. Daniel Feiken, returns to Kenya after a year away, and finds reasons to be optimistic that Kenya's recent introduction of pneumococcal vaccine will result in a reduction in child mortality and a corresponding rise in the Kenyan economy. Read his story here. IVAC Extends Condolences to United Nations Staff in Abuja, Nigeria August 29, 2011 The International Vaccine Access Center extends its deepest condolences to the United Nations staff, their families and colleagues, who suffered in the attack in Abuja, Nigeria, on Friday, August 25th. Read Previous EntriesOur Partners and Sponsors
|
